Emerging drugs for managing kidney disease in patients with diabetes.

about

Bedside-to-Bench Translational Research for Chronic Heart Failure: Creating an Agenda for Clients Who Do Not Meet Trial Enrollment Criteria Inflammation in diabetic nephropathy: moving toward clinical biomarkers and targets for treatment.Diabetic kidney disease.

P2860

Q26797153-8C21E963-6C8F-46D0-A4AD-6B735F264560 Q38255902-C4EC4DB7-B599-45F1-93AB-9672747B1BB1 Q43721013-6F4EAF33-A6E7-45DF-B819-F3F455F2D31E

P2860

Emerging drugs for managing kidney disease in patients with diabetes.

Item

http://www.wikidata.org/entity/Q38075029

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Emerging drugs for managing kidney disease in patients with diabetes.

@en

type

Item

label

Emerging drugs for managing kidney disease in patients with diabetes.

@en

prefLabel

Emerging drugs for managing kidney disease in patients with diabetes.

@en

P1476

Emerging drugs for managing kidney disease in patients with diabetes

@en

P2093

Merlin C Thomas

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk

Avosentan reduces albumin excretion in diabetics with macroalbuminuria

RKI-1447 Is a Potent Inhibitor of the Rho-Associated ROCK Kinases with Anti-Invasive and Antitumor Activities in Breast Cancer

Biochemistry and molecular cell biology of diabetic complications

Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

Oxidative stress as a major culprit in kidney disease in diabetes

Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy.

Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria

Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss.

P304

55-70

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728214.2013.762356

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Merlin Thomas

P577

2013-01-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23330907

http://www.w3.org/2001/XMLSchema#string

Emerging drugs for managing kidney disease in patients with diabetes.

about

P2860

P2860

Emerging drugs for managing kidney disease in patients with diabetes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698